💊 Psilocybin just outperformed SSRIs in the largest head-to-head trial ever conducted. What this actually means.
Not hype. Not anecdote. A Phase IIb randomised controlled trial published in The Lancet.
The COMP360 trial (2023, COMPASS Pathways) enrolled 233 patients with treatment-resistant depression receiving 1mg, 10mg, or 25mg psilocybin in a single session.
At 3 weeks post-treatment:
— 25mg group: 29% clinical response (vs. 8% control)
— 24% achieved full remission
For context: SSRIs achieve 40–60% response rates — but require daily dosing for months. Psilocybin: one session.
The mechanism: psilocybin binds 5-HT2A receptors and temporarily increases neural plasticity. Depression is rigid negative thought looping. Psilocybin appears to reset the loop.
The challenges remain real:
— Long-term data still limited
— Requires trained therapeutic support
— 37% of 25mg participants experienced serious adverse events
This is not a cure. Not yet a treatment. But the most promising clinical direction in psychiatry in 30 years.
The mushroom didn’t change yesterday.
Our willingness to study it did.
Should psilocybin-assisted therapy be available through public healthcare? I want to hear genuinely different views. 🧠
#MycelNet #Psilocybin #MagicMushrooms #MentalHealth #Depression #PsychedelicTherapy #ClinicalTrial #Mycology #Fungi #Mushroom
